Manuel López Figueroa

Manuel López-Figueroa, is the Chief Operating Officer (COO) of IMIDomics.

In addition, Dr. Lopez-Figueroa is the scientific liaison for the Pritzker Neuropsychiatric Disorders Research Consortium, a collaborative research enterprise comprised of a group of leaders in psychiatry, neuroscience, and genetics from Stanford University, the University of Michigan, Cornell University, the HudsonAlpha Institute for Biotech, and the University of California, Irvine.

López-Figueroa is an advisor to Bay City Capital. He had previously served as the firm’s Managing Director since 2001. Bay City Capital is one of the world’s leading life sciences investment firms investing in more than 100 companies and with more than $1.6 billion under management.

He has entrepreneurial experience in starting several innovative companies in the portfolio, including BrainCells Inc. and Synchronicity Pharmaceuticals. Dr. Lopez-Figueroa participated in successful investments including Ion Torrent Systems, (acquired by Life Technologies), NextWave Pharmaceuticals (acquired by Pfizer), and Civitas (acquired by Acorda Therapeutics).

Manuel has more than 25 years of experience in the field of neurosciences, has won numerous awards during his academic research career and has published extensively. He completed his postdoctoral work at the University of Michigan and the University of Copenhagen, Denmark. Dr. Lopez received a doctorate in Medicine and Surgery and a master’s degree in Molecular and Cellular Biology from the Universities of Las Palmas and La Laguna, Spain, respectively.

He is a member of the boards of Oryzon Genomics (ORY. MC) and Orfan Biotech (a subsidiary of BridgeBio’s Pharma (BBIO)). He is an investment advisor at Nina Capital.